Friday, July 31, 2026

Heat-Related Illnesses Surge: Tips to Stay Cool During the Heatwave!

After rainfall, high humidity combined with a heatwave can elevate the perceived temperature, increasing the risk of heat-related illnesses.

North Korea Media May Open to the Public as Seoul Pushes to Ease Access Restrictions

South Korea is pushing to open North Korean media access, with new legislation aimed at easing restrictions and enhancing public understanding.

Kim Jong-un And Ju-ae Attend Nuclear Submarine Site In Same Clothes As Six Days Ago: Hidden “No. 1 Route”

North Korea's nuclear submarine unveiling reflects strategic messaging to mask Kim Jong Un's movements while showcasing military and economic progress.

Jung Eun Kim

South Korea’s Pharmaceutical Future: 500 Million USD Investment from Eli Lilly to Boost K-Bio Innovation

South Korea partners with Eli Lilly to boost biotech and pharma industries, investing $500M to enhance innovation and healthcare access.

How Keytruda is Revolutionizing Cancer Treatment: Expanded Coverage for Stomach Cancer in 2026

Keytruda's insurance coverage expands to stomach cancer, solidifying its status as a leading universal immunotherapy for various cancers.

Ubicare Targets 80%+ Operating Profit Growth in 2026 — Here’s What’s Changing in Its EMR and Platform Play

Ubicare reported a 46% increase in operating profit for 2025, driven by optimized revenue structures and plans for AI solutions in 2026.

How Lunit’s AI is Transforming Early Breast Cancer Risk Assessment: Key Findings from ECR 2026

Lunit presents 21 research findings at ECR 2026, showcasing AI's potential in breast cancer risk assessment and screening innovations.

A New Adult Pneumococcal Shot Hits Korea: 21-Valent Coverage Targeting 80% of Adult Invasive Cases

Korean MSD launches Capvaxive, a 21-valent vaccine for adults to prevent pneumococcal diseases, targeting high-risk populations.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Korean Health Insurance Corporation Wins Platinum Award for Sustainability Report: What This Means for ESG Practices

NHIS wins Platinum Award at LACP Vision Awards for its sustainability report, achieving a perfect score in seven categories.

ABL209 Receives FDA Approval: What This Dual Antibody ADC Means for Cancer Treatment

ABL Bio receives FDA approval for ABL209, a bispecific antibody-drug conjugate, advancing ADC development for solid tumors.

Korea’s Olive Young Gets a New Sleep Aid: Daewon Launches Honey Sleep Shot Backed by a Study

Daewon Health launches Honey Sleep Shot, a plant-based sleep aid, in 900 Olive Young stores, targeting sleep issues for modern consumers.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

GCCell Secures Groundbreaking Patent for Next-Gen Cell Therapy: What It Means for the Future of Immunotherapy

GC Cell has completed the registration of core technology patents for next-gen cell and gene therapies in South Korea and Japan.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

A New Hair-Growth Pathway?: JW0061 Targets GFRA1 After 7.2x Organoid Results and a 39% Animal Boost

JW Pharmaceutical's hair loss treatment JW0061 gains FDA approval for clinical trials, promising innovative growth stimulation for men and women.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Top News

- Our Sponsors Ad -

Follow us